310 related articles for article (PubMed ID: 33949790)
1. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
Häußler V; Ufer F; Pöttgen J; Wolschke C; Friese MA; Kröger N; Heesen C; Stellmann JP
Ann Clin Transl Neurol; 2021 Jun; 8(6):1269-1278. PubMed ID: 33949790
[TBL] [Abstract][Full Text] [Related]
2. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
[TBL] [Abstract][Full Text] [Related]
3. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
4. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
5. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
6. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT.
Kvistad SAS; Burman J; Lehmann AK; Tolf A; Zjukovskaja C; Melve GK; Bø L; Torkildsen Ø
J Neurol Neurosurg Psychiatry; 2022 Aug; 93(8):844-848. PubMed ID: 35508373
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
8. Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis.
Giedraitiene N; Kizlaitiene R; Peceliunas V; Griskevicius L; Kaubrys G
Sci Rep; 2020 Dec; 10(1):21286. PubMed ID: 33277590
[TBL] [Abstract][Full Text] [Related]
9. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis.
Alping P; Burman J; Lycke J; Frisell T; Piehl F
Neurology; 2021 Mar; 96(11):e1574-e1584. PubMed ID: 33514645
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
[TBL] [Abstract][Full Text] [Related]
12. [Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].
Stellmann JP; Stürner KH; Ufer F; Havemeister S; Pöttgen J; Ayuk Ayuketang F; Kröger N; Friese MA; Heesen C
Nervenarzt; 2015 Aug; 86(8):989-96. PubMed ID: 25956824
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
[TBL] [Abstract][Full Text] [Related]
14. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
[TBL] [Abstract][Full Text] [Related]
15. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
Boffa G; Sbragia E; Raiola AM; Varaldo R; Capello E; Gallo P; Granella F; Mancardi G; Inglese M
Mult Scler; 2021 Jun; 27(7):1145-1148. PubMed ID: 32840405
[TBL] [Abstract][Full Text] [Related]
19. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
Zhukovsky C; Sandgren S; Silfverberg T; Einarsdottir S; Tolf A; Landtblom AM; Novakova L; Axelsson M; Malmestrom C; Cherif H; Carlson K; Lycke J; Burman J
J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):189-194. PubMed ID: 33106366
[TBL] [Abstract][Full Text] [Related]
20. The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation.
Pastelín-Martínez ML; Gallardo-Pérez MM; Gómez-de-León A; Olivares-Gazca JC; Hernández-Flores EJ; Sánchez-Bonilla D; Montes-Robles M; Robles-Nasta M; Ocaña-Ramm G; Soto-Olvera S; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Diagnosis (Berl); 2024 May; 11(2):164-170. PubMed ID: 38230519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
